A randomized phase 1b/2 study evaluating the safety and efficacy of doxorubicin (dox) with or without olaratumab (imc3g3), a human anti-platelet-derived growth factor a (pdgfra) monoclonal antibody, in advanced soft tissue sarcoma (sts)

被引：0
|
作者：
Tap, W. [1 ]
Jones, R. L. [2 ]
Chmelowski, B. [3 ]
Elias, A. A. [4 ]
Adkins, D. [5 ]
Van Tine, B. A. [5 ]
Agulnik, M. [6 ]
Cooney, M. [7 ]
Livingston, M. B. [8 ]
Pennock, G. [9 ]
Quin, A. [10 ]
Shahir, A. [11 ]
Ilaria, R., Jr. [12 ]
Conti, I. [12 ]
Schwartz, G. K. [12 ,13 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Fred Hutchinson Canc Res Cente, Seattle, WA USA
[3] UCLA Melanoma Sarcoma Program, Los Angeles, CA USA
[4] Univ Colorado, Ctr Canc, Aurora, CO USA
[5] Washington Univ, Sch Med, St Louis, MO USA
[6] Northwestern Univ, Chicago, IL 60611 USA
[7] Univ Hosp Case Med Ctr, Cleveland, OH USA
[8] Carolinas HealthCare Syst, Charlotte, NC USA
[9] Levine Canc Inst, Charlotte, NC USA
[10] Eli Lilly & Co, Bridgewater, NJ USA
[11] Eli Lilly & Co, Erl Wood, England
[12] Eli Lilly & Co, Indianapolis, IN 46285 USA
[13] Columbia Univ, Sch Med, New York, NY USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
0574
引用
收藏
页码：174 / 174
页数：1
相关论文
共 17 条
  • [1] A randomized phase 1b/2 study evaluating the safety and efficacy of doxorubicin (dox) with or without olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (pdgfrα) monoclonal antibody, in advanced soft tissue sarcoma (sts)
    Tap, W.
    Jones, R. L.
    Chmielowski, B.
    Elias, A. D.
    Adkins, D.
    Van Tine, B. A.
    Agulnik, M.
    Cooney, M.
    Livingston, M. B.
    Pennock, G.
    Qin, A.
    Shahir, A.
    Ilaria, R., Jr.
    Conti, I.
    Schwartz, G.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS)
    Tap, William D.
    Jones, Robin L.
    Chmielowski, Bartosz
    Elias, Anthony D.
    Adkins, Douglas
    Van Tine, Brian Andrew
    Agulnik, Mark
    Cooney, Matthew M.
    Livingston, Michael B.
    Pennock, Gregory K.
    Qin, Amy
    Shahir, Ashwin
    Ilaria, Robert L.
    Conti, Ilaria
    Cosaert, Jan
    Schwartz, Gary K.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] A phase Ib/II study evaluating the efficacy of doxorubicin (D) with or without a human anti-PDGFRα monoclonal antibody olaratumab (IMC-3G3) in the treatment of advanced soft tissue sarcoma (STS).
    Tap, William D.
    Van Tine, Brian Andrew
    Elias, Anthony D.
    Livingston, Michael B.
    Agulnik, Mark
    Cooney, Matthew M.
    Chmielowski, Bartosz
    Brenner, Andrew Jacob
    Pennock, Gregory K.
    Somaiah, Neeta
    Dang, Long H.
    Tian, Gary G.
    Jones, Robin Lewis
    Okuno, Scott H.
    Loizos, Nick
    Nippgen, Johannes
    Schwartz, Gary K.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Randomized phase II trial of pegylated liposomal doxorubicin (PLD) with or without anti-platelet-derived growth factor receptor-alpha (PDGFR-alpha) monoclonal antibody IMC-3G3 in platinum-refractory/resistant advanced ovarian cancer
    McGuire, W. P.
    Shah, G. D.
    Loizos, N.
    Youssoufian, H.
    Rowinsky, E. K.
    Gore, M. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Phase I study of IMC-3G3, an IgG1 monoclonal antibody targeting platelet-derived growth factor alpha (PDGFRa) in patients with advanced solid malignancies
    Chiorean, E.
    Sweeney, C.
    Youssoufian, H.
    Fox, F.
    Katz, T.
    Rowinsky, E.
    Amato, R.
    EJC SUPPLEMENTS, 2008, 6 (12): : 162 - 162
  • [6] Enhanced antitumor activity of anti-platelet derived growth factor receptor alpha antibody, IMC-3G3, in combination with doxorubicin against a human soft-tissue sarcoma xenograft model.
    Tonra, J
    Deevi, D
    Carrick, F
    Li, HL
    Hicklin, D
    Kussie, P
    Loizos, N
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8981S - 8981S
  • [7] ANNOUNCE 2: An open-label phase 1b, and a randomized, double-blind phase 2 study of olaratumab with gemcitabine plus docetaxel in the treatment of patients with advanced soft tissue sarcoma (STS)
    Redondo, A.
    Valverde Morales, C.
    Hindi, N.
    Lopez-Martin, J. A.
    Honigschmidt, G.
    Zeng, Y.
    Chen, J.
    Tai, D. F.
    Mo, G.
    Ilaria, R., Jr.
    Pillay, N. S.
    Drove, N.
    Jamarik, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] Phase I study of doxorubicin (D) plus anti-insulin-like growth factor 1 receptor (IGF-1R) antibody cixutumumab (IMC-A12) in advanced soft tissue sarcoma (STS)
    Chugh, Rashmi
    Griffith, Kent A.
    Brockstein, Bruce
    Undevia, Samir D.
    Stadler, Walter Michael
    Schuetze, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] A randomized phase 2 study of a human antiplatelet-derived growth factor α (PDGFRα) monoclonal antibody (olaratumab, IMC-3G3) with paclitaxel/carboplatin or paclitaxel/carboplatin alone in previously untreated patients with advanced non-small cell lung cancer (NSCLC).
    Gerber, David E.
    Campbell, Toby Christopher
    Swanson, Paul
    Lopez-Chavez, Ariel
    Wong, Lucas
    Dowlati, Afshin
    Qin, Amy
    Cosaert, Jan G. C. E.
    Baggstrom, Maria Quintos
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Results of the phase 1b soft-tissue sarcoma (STS) portion of the global randomized, double-blind, placebo-controlled study of tazemetostat (TAZ) plus doxorubicin (DOX) as frontline therapy for advanced epithelioid sarcoma (ES).
    Chawla, St P.
    Falchook, Gerald Steven
    Burgess, Melissa Amber
    Chen, James Lin
    Jones, Robin Lewis
    Chua, Victoria S.
    Tapia, Coya
    Ainscough, Jessica
    Hamlett, Anthony
    Merchant, Melinda S.
    Chugh, Rashmi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12